# BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

> **NCT05530395** · — · UNKNOWN · sponsor: **Ignacio Puche Sanz** · enrollment: 300 (estimated)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DIAGNOSTIC_TEST:** Testosterone levels

## Key facts

- **NCT ID:** NCT05530395
- **Lead sponsor:** Ignacio Puche Sanz
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-09-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05530395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05530395, "BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05530395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*